Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. Issue 2 (December 2015) - Sznol, Mario; Fishman, Mayer; Escudier, Bernard; McDermott, David; Kluger, Harriet; Stadler, Walter; Perez-Gracia, Jose; McNeel, Douglas; Curti, Brendan; Harrison, Michael; Plimack, Elizabeth; Appleman, Leonard; et al.